CMS reiterated that guidance is forthcoming and that they will try to be more specific. They also encouraged her and other providers to review patient medical records to determine if the encounter satisfies the requirements for billing G2211. As with underwater biosimilars, the ACR is considering building an ad hoc coalition of like-minded societies to put more pressure on CMS to remove these harmful restrictions. ACR guidance on billing for G2211 can be found here.
Call to Action
The ACR encourages members to email the CMS and utilize the ACR’s Legislative Action Center to voice any concerns they have about these issues. It also encourages members to peruse our Q/A on billing for G2211 and our plan of action on underwater biosimilars for further guidance.
